• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
AND
Click for more information
0.00% $2.49

ANSARADA GROUP LIMITED - News & Media

Currently unlisted. watchlist Created with Sketch. Add to my watchlist

Ansarada is a SaaS Platform with products used by the world’s top companies, advisors &... Ansarada is a SaaS Platform with products used by the world’s top companies, advisors & governments to govern their most critical information & processes in Deals & Transaction Management, Board Management, Compliance & Tenders, including by 87 of the top 100 ASX & 10 of the top 10 investment banks. Ansarada enables organisations across the globe to be run more efficiently, with reduced risk and an increased ability to make fast confident decisions.More

No News & Media currently available.

Top Stories

Iress runs 'hot' for Wealth Within's stock tips

Financial services software play Iress (ASX:IRE) is the HotCopper Hot Stock tip this week from Wealth Within's chief analyst Dale Gillham and senior analyst Fil Tortevski.
Failure to report prompts ASX to impose multiple company suspensions The ASX today told more than 20 companies across many sectors that it would be imposing suspensions on them
Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia Coda Minerals (ASX:COD) CEO, Chris Stevens, joins The Market Online to discuss the company's current rights issue, and how the capital from this raise will be used to further its copper exploration in South Australia. In addition, Chris talks through the journey the company has taken over the last few years since listing until now.
Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals Actinogen Medical is developing a promising oral treatment for Alzheimer's and depression and is accelerating clinical trials with new capital.
Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.